Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W McIntyre

Showing results (471-480 of 505) with videos related to

Pageof 51
Sort By:
Journal of Medicinal Chemistry|July 18, 2019
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Biochemistry|August 25, 2004
Selective Itk inhibitors block T-cell activation and murine lung inflammationTai-An Lin, Kim W McIntyre, Jagabandhu Das, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Canadian Journal of Kidney Health and Disease|January 20, 2026
Randomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research ProtocolPaul N Bennett, Jarrin D Penny, Christopher W McIntyre, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Science Translational Medicine|July 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainJames R Burke, Lihong Cheng, Kathleen M Gillooly, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
Pageof 51

Showing results (471-480 of 505) with videos related to

Sort By:
Pageof 51
Journal of Medicinal Chemistry|July 18, 2019
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Biochemistry|August 25, 2004
Selective Itk inhibitors block T-cell activation and murine lung inflammationTai-An Lin, Kim W McIntyre, Jagabandhu Das, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Canadian Journal of Kidney Health and Disease|January 20, 2026
Randomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research ProtocolPaul N Bennett, Jarrin D Penny, Christopher W McIntyre, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Science Translational Medicine|July 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainJames R Burke, Lihong Cheng, Kathleen M Gillooly, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
Pageof 51